UBS Group
TVTX icon

UBS Group’s Travere Therapeutics TVTX Stock Holding History

UBS Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-67,500
Closed -$607K – 10030
2023
Q4 		$607K Sell
67,500
-71,900
-52% -$524K ﹤0.01% 4941
2023
Q3 		$1.25M Buy
139,400
+46,100
+49% +$650K ﹤0.01% 3883
2023
Q2 		$1.43M Buy
+93,300
New +$1.7M ﹤0.01% 3873
2016
Q3 		– Sell
-180,000
Closed -$3.21M – 7945
2016
Q2 		$3.21M Buy
+180,000
New +$2.91M ﹤0.01% 2376
2015
Q1 		– Sell
-500
Closed -$6K – 9387
2014
Q4 		$6K Buy
+500
New +$5.17K ﹤0.01% 8856

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's TVTX Position: Q1 2026 in Review

UBS Group increased its Travere Therapeutics (TVTX) stake by 103% in Q1 2026, buying an estimated $13M and bringing the position to 856,757 shares worth $25.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

UBS Group first reported a position in TVTX in Q2 2015 and has held it in 43 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • UBS Group held 856,757 shares of Travere Therapeutics worth $25.5M as of Q1 2026.
  • UBS Group bought 434,138 Travere Therapeutics shares in Q1 2026, an estimated $13M.
  • Travere Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2331 holding.
  • UBS Group first reported a position in Travere Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.